Yes, ceftriaxone (Rocephin) provides excellent coverage against Proteus mirabilis.
Ceftriaxone is FDA-approved and highly effective for treating infections caused by Proteus mirabilis, including urinary tract infections, skin and soft tissue infections, lower respiratory tract infections, bone and joint infections, and bacteremia 1.
Microbiological Activity
Ceftriaxone demonstrates robust in vitro activity against Proteus mirabilis:
- Historical data from the early 1980s showed ceftriaxone was as active or more active than other third-generation cephalosporins (cefotaxime, ceftazidime) against P. mirabilis 2, 3
- A 1981 study found ceftriaxone was slightly more active than cefotaxime against P. mirabilis 3
- The drug maintains consistent activity against this organism, with no significant changes in MIC90 values observed over time, unlike some other pathogens that have developed resistance 4
Clinical Evidence
Clinical efficacy is well-established. In a study of 35 serious bacterial infections, ceftriaxone achieved a 91% response rate, with P. mirabilis among the successfully treated pathogens 5. The FDA label specifically lists P. mirabilis as a susceptible organism across multiple infection types 1.
Guideline Support
Multiple clinical guidelines endorse ceftriaxone for infections where P. mirabilis is a likely pathogen:
- Intra-abdominal infections: Third-generation cephalosporins including ceftriaxone (plus metronidazole) are recommended for high-severity community-acquired infections 6
- Endocarditis: For susceptible strains of E. coli or P. mirabilis, a combination of either ampicillin or a broad-spectrum cephalosporin with an aminoglycoside is recommended 7
Important Caveats
While ceftriaxone covers P. mirabilis effectively, be aware that:
- Proteus vulgaris (a different species) is also listed as susceptible but may have different resistance patterns 1
- For serious infections like endocarditis, combination therapy with an aminoglycoside (typically gentamicin) is recommended rather than ceftriaxone monotherapy 7
- The standard dosing is 1-2 g IV daily, with higher doses reserved for severe infections or meningitis 1
Bottom line: Ceftriaxone is an excellent choice for P. mirabilis infections and is specifically FDA-approved for this indication across multiple body sites.